{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:11:02Z","timestamp":1778299862641,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    Proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score\u2010matched study (Clalit Health Services, Israel, 2010\u20132023) comparing PCSK9 mAbs to ezetimibe. Adults prescribed PCSK9 mAbs for 6\u2009months or more were matched 1:3 to ezetimibe\u2010treated patients without prior cancer, applying a 1\u2010year latency. The cohort included 9,876 patients (2,469 PCSK9 mAb; 7,407 ezetimibe; mean age 65). During a median 4.6\u2010year follow\u2010up, cancer occurred in 12% of PCSK9 mAb users and 11% of ezetimibe users (HR 1.09 [95% CI, 0.95\u20131.25]). In sex\u2010stratified analysis, men on PCSK9 mAbs had a higher cancer incidence (12.5% vs. 10.3%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.03); no difference was observed in women. All\u2010cause mortality was significantly lower in the PCSK9 mAb group (3% vs. 5%; HR 0.65 [95% CI, 0.54\u20130.80]). Post\u2010cancer\u2010diagnosis mortality did not differ. In this large cohort, PCSK9 mAb therapy appeared safe regarding overall cancer risk and was associated with a significant reduction in all\u2010cause mortality; the slightly higher cancer incidence in men may likely be attributed to a higher prevalence of baseline risk factors.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70232","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:54:03Z","timestamp":1770728043000},"page":"1547-1554","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proprotein Convertase Subtilisin\/Kexin Type 9 (\n                    <scp>PCSK9<\/scp>\n                    ) Inhibition and Cancer Risk: Insights from a Large Propensity\u2010Matched Cohort Study"],"prefix":"10.1002","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7995-789X","authenticated-orcid":false,"given":"Inbar","family":"Nardi Agmon","sequence":"first","affiliation":[{"name":"Division of Cardiology Rabin Medical Center  Petach Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center Toronto General Hospital, University Health Network, University of Toronto  Toronto Ontario Canada"},{"name":"Lev Leviev Cardiovascular and Thoracic Center Sheba Medical Center  Tel Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Gurevitz","sequence":"additional","affiliation":[{"name":"Division of Cardiology Rabin Medical Center  Petach Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzippy","family":"Shochat","sequence":"additional","affiliation":[{"name":"Research Authority Rabin Medical Center  Petach Tikva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiri","family":"Kushnir","sequence":"additional","affiliation":[{"name":"Research Authority Rabin Medical Center  Petach Tikva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Witberg","sequence":"additional","affiliation":[{"name":"Division of Cardiology Rabin Medical Center  Petach Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amos","family":"Levi","sequence":"additional","affiliation":[{"name":"Division of Cardiology Rabin Medical Center  Petach Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Gilon","sequence":"additional","affiliation":[{"name":"Heart Institute, Hadassah Medical Center and Faculty of Medicine Hebrew University  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Kornowski","sequence":"additional","affiliation":[{"name":"Division of Cardiology Rabin Medical Center  Petach Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[{"name":"Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center Toronto General Hospital, University Health Network, University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Abdel Qadir","sequence":"additional","affiliation":[{"name":"Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center Toronto General Hospital, University Health Network, University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaza","family":"Iakobishvili","sequence":"additional","affiliation":[{"name":"Department of Community Cardiology Tel Aviv Jaffa District, Clalit Health Services  Tel Aviv Israel"},{"name":"Faculty of Health Sciences Ben Gurion University of the Negev  Be'er Sheva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00119"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00339-z"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2570"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17412"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12148-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188581"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156064"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.577420"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153727"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02435-0"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-021-00821-2"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2911-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.121252"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106916"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00977-6"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01892-9"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14259"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6310"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061620"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1747"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01017-x"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70232","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:30:54Z","timestamp":1778297454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/cpt.70232"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70232","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"2025-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}